Alpha-1-antitrypsin deficiency: Diagnosis and therapy of the lung disease;Alpha-1-Antitrypsin-Mangel: Diagnose und Therapie der pulmonalen Erkrankung

Pneumologie

Volumn 63, Issue 6, 2009, Pages 335-345

  Schroth, S ^a   Koczulla, R ^a   Herr, C ^a   Greulich, T ^a   Walthers, E M ^a   Vogelmeier, C ^a   Bals, R ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ELASTASE INHIBITOR; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PROTEIN; PROTEINASE; SERPINA1 PROTEIN; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EMPHYSEMA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPERCAPNIA; HYPOXIA; INFLUENZA VACCINATION; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MORTALITY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PANNICULITIS; PHENOTYPE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; HUMANS; LUNG DISEASES;

EID: 69249229878     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1214718     Document Type: Review

References (30)

1. Campbell EJ, Campbell MA, Boukedes SS et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest 1999; 104: 337-344
2. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103: 2136-2141
3. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236
4. Mahadeva R, Lomas DA. Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998; 53: 501-505
5. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax 2004; 59: 529-535
6. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352
7. American Thoracic Society/European Respiratory Society Statement. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900
8. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259-264
9. Mahadeva R, Atkinson C, Li Z et al. Polymers of Z alpha1- antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166: 377-386
10. Blanco I, de Serres FJ, Fernandez-Bustillo E et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1- antitrypsin deficiency in European countries. ERJ 2006; 27: 77-84
11. Stockley RA, Luisetti M, Miravitlles M et al. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. ERJ 2007; 29: 582-586
12. McElvaney NG, Stoller JK, Buist AS et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394-403
13. Bals R, Koczulla R, Kotke V et al. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med 2007; 101: 1217-1218
14. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128: 1179-1186
15. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200000 infants. N Engl J Med 1976; 294: 1316-1321
16. Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency. Acta Paediatr 1998; 87(11): 1120-1124
17. Bernspang E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha- 1-antitrypsin deficiency. Respir Med 2007; 101: 1971-1976
18. Anonymous. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75: 397-415
19. Vogelmeier C, Buhl R, Criée CP et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysemen (COPD). Pneumologie 2007; 61: e1-e440
20. Andreas S, Batra A, Behr J et al. Tabakentwöhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie 2008; 62: 255-272
21. Magnussen H, Goeckenjan G, Kohler D et al. Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 2001; 55: 454-464
22. Tutic M, Bloch KE, Lardinois D et al. Long-term results after lung volume reduction surgery in patients with alpha1- antitrypsin deficiency. J Thorac Cardiovasc Surg 2004; 128: 408-413
23. Sandhaus RA. alpha1-Antitrypsin deficiency. 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax 2004; 59: 904-909
24. Wencker M, Banik N, Buhl R et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11: 428-433
25. Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49-59
26. Wencker M, Fuhrmann B, Banik N et al. Longitudinal follow- up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737-744
27. Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1- AT study group. Eur Respir J 1997; 10: 2260-2263
28. Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472
29. Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J 2009; Feb. 5 [Epub]
30. Koczulla R, Bittkowski N, Andress J et al. Das Deutsche Register für Personen mit Alpha-1-Antitrypsin-Mangel - eine Ressource für die Versorgungsforschung. Pneumologie 2008; 62: 655-658